Concerns about serum androgens monitoring during testosterone replacement treatments in hypogonadal male athletes: A pilot study

Journal of Sexual Medicine

Volumn 9, Issue 3, 2012, Pages 873-886

  Di Luigi, Luigi ^a   Sgrò, Paolo ^a   Aversa, Antonio ^b   Migliaccio, Silvia ^a   Bianchini, Serena ^a   Botrè, Francesco ^b   Romanelli, Francesco ^b   Lenzi, Andrea ^b  

^a UNIVERSITY OF ROME FORO ITALICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bioavailable Testosterone; DHT; Doping; Free Testosterone; Sport; Testosterone

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ESTRADIOL; GLUCURONIDE; TESTOSTERONE; TESTOSTERONE ENANTATE;

ANDROGEN BLOOD LEVEL; ANDROGEN THERAPY; ARTICLE; ATHLETE; CAUCASIAN; CLINICAL ARTICLE; DRUG EFFICACY; HUMAN; HYPOGONADISM; MALE; PILOT STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

EID: 84857646638     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02600.x     Document Type: Article

References (50)

1. Cunningham GR, Toma SM. Clinical review: Why is androgen replacement in males controversial? J Clin Endocrinol Metab 2011;96:38-52.
2. Gooren LJ, Behre HM. Testosterone treatment of hypogonadal men participating in competitive sports. Andrologia 2008;40:195-9.
3. Di Luigi L, Sgrò P, Fierro V, Bianchini S, Battistini G, Magini V, Jannini EA, Lenzi A. Prevalence of undiagnosed testosterone deficiency in aging athletes: Does exercise training influence the symptoms of male hypogonadism? J Sex Med 2010;7:2591-601.
4. Zitzmann M, Nieschlag E. Effects of androgen replacement on metabolism and physical performances in male hypogonadism. J Endocrinol Invest 2003;26:886-92.
5. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clin Endocrinol 2005;63:280-93.
6. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001;281:E1172-81.
7. Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FC. Testosterone replacement therapy: Current trends and future directions. Hum Reprod Update 2004;10:409-19.
8. Crewther BT, Cook C, Cardinale M, Weatherby RP, Lowe T. Two emerging concepts for elite athletes: The short-term effects of testosterone and cortisol on the neuromuscular system and the dose-response training role of these endogenous hormones. Sports Med 2011;41:103-23.
9. Darby E, Anawalt BD. Male hypogonadism: An update on diagnosis and treatment. Treat Endocrinol 2005;4:293-309.
10. Seftel AD. Male hypogonadism. Part I: Epidemiology of hypogonadism. Int J Impot Res 2006;18:115-20.
11. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59.
12. Gooren LJ. Advances in testosterone replacement therapy. Front Horm Res 2009;37:32-51.
13. Gooren LJ, Bunck MC. Androgen replacement therapy: Present and future. Drugs 2004;64:1861-91.
14. Nieschlag E. Testosterone treatment comes of age: New options for hypogonadal men. Clin Endocrinol 2006;65:275-81.
15. Isidori AM, Lenzi A. Testosterone replacement therapy: What we know is not yet enough. Mayo Clin Proc 2007;82:11-3.
16. Di Luigi L, Romanelli F, Lenzi A. Androgenic-anabolic steroids abuse in males. J Endocrinol Invest 2005;28(3 suppl):81-4.
17. Modlinski R, Fields KB. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Curr Sports Med Rep 2006;5:104-9.
18. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-92.
19. Di Luigi L, Sgrò P, Romanelli F, Mazzarino M, Donati F, Braganò MC, Bianchini S, Fierro V, Casasco M, Botrè F, Lenzi A. Urinary and serum hormones profiles after testosterone enanthate administration in male hypogonadism: Concerns on the detection of doping with testosterone in treated hypogonadal athletes. J Endocrinol Invest 2009;32:445-53.
20. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004;34:513-54.
21. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469-78.
22. Nieschlag E, Cüppers HJ, Wiegelmann W, Wickings EJ. Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res 1976;7:138-45.
23. Behre HM, Nieschlag E. Comparative pharmacokinetic of androgen preparations: Applications of computer analysis and simulation. In: Nieschlag E, Behre HM, eds. Testosterone action, deficiency, substitution. Berlin: Springer-Verlag; 1990:115-35.
24. Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: Application of gel at one site versus four sites: A general clinical research center study. J Clin Endocrinol Metab 2000;85:964-9.
25. Seftel A. Male hypogonadism. Part II: Etiology, pathophysiology, and diagnosis. Int J Impot Res 2006;18:223-8.
26. Di Luigi L, Guidetti L, Pigozzi F, Baldari C, Casini A, Nordio M, Romanelli F. Acute amino acids supplementation enhances pituitary responsiveness in athletes. Med Sci Sports Exerc 1999;31:1748-54.
27. Di Luigi L, Rossi C, Sgrò P, Fierro V, Romanelli F, Baldari C, Guidetti L. Do non-steroidal anti-inflammatory drugs influence the steroid hormone milieu in male athletes? Int J Sports Med 2007;28:809-14.
28. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801-10.
29. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
30. Mazzarino M, Botrè F. A fast liquid chromatographic/mass spectrometric screening method for the simultaneous detection of synthetic glucocorticoids, some stimulants, anti-oestrogen drugs and synthetic anabolic steroids. Rapid Commun Mass Spectrom 2006;20:3465-76.
31. Van Renterghem P, Van Eenoo P, Geyer H, Schänzer W, Delbeke FT. Reference ranges for urinary concentrations and ratios of endogenous steroids, which can be used as markers for steroid misuse, in a Caucasian population of athletes. Steroids 2010;75:154-63.
32. Hackney AC. Effects of endurance exercise on the reproductive system of men: The "exercise-hypogonadal male condition". J Endocrinol Invest 2008;31:932-8.
33. Morelli A, Corona G, Filippi S, Ambrosini S, Forti G, Vignozzi L, Maggi M. Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Invest 2007;30:880-8.
34. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500-10.
35. Rolf C, Kemper S, Lemmnitz G, Eickenberg U, Nieschlag E. Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men. Eur J Endocrinol 2002;146:673-9.
36. Chik Z, Johnston A, Tucker AT, Chew SL, Michaels L, Alam CA. Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. Br J Clin Pharmacol 2006;61:275-9.
37. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980;51:1335-9.
38. Palonek E, Gottlieb C, Garle M, Björkhem I, Carlström K. Serum and urinary markers of exogenous testosterone administration. J Steroid Biochem Mol Biol 1995;55:121-7.
39. Kicman AT, Brooks RV, Collyer SC, Cowan DA, Nanjee MN, Southan GJ, Wheeler MJ. Criteria to indicate testosterone administration. Br J Sports Med 1990;24:253-64.
40. Dehennin L, Matsumoto AM. Long-term administration of testosterone enanthate to normal men: Alterations of the urinary profile of androgen metabolites potentially useful for detection of testosterone misuse in sport. J Steroid Biochem Mol Biol 1993;44:179-89.
41. Behre HM, Wang C, Handelsman DJ, Nieschlag E. Pharmacology of testosterone preparations. In: Nieschlag E, Behre HM, eds. Testosterone action, deficiency, substitution. Cambridge: Cambridge University Press; 2004:405-44.
42. Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, Fabbri A. Leptin and androgens in male obesity: Evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999;84:3673-80.
43. von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: A phase II study. J Androl 2002;23:419-25.
44. Fennell C, Sartorius G, Ly LP, Turner L, Liu PY, Conway AJ, Handelsman DJ. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men. Clin Endocrinol (Oxf) 2010;73:102-9.
45. Yassin AA, Saad F. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate. Andrologia 2007;39:181-4.
46. Vingren JL, Kraemer WJ, Ratamess NA, Anderson JM, Volek JS, Maresh CM. Testosterone physiology in resistance exercise and training: The up-stream regulatory elements. Sports Med 2010;40:1037-53.
47. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren LJ. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675-85.
48. Van Renterghem P, Van Eenoo P, Sottas PE, Saugy M, Delbeke F. A pilot study on subject-based comprehensive steroid profiling: Novel biomarkers to detect testosterone misuse in sports. Clin Endocrinol (Oxf) 2011;75:134-40.
49. Sottas PE, Saugy M, Saudan C. Endogenous steroid profiling in the athlete biological passport. Endocrinol Metab Clin North Am 2010;39:59-73.
50. Bowers LD. Testosterone doping: Dealing with genetic differences in metabolism and excretion. J Clin Endocrinol Metab 2008;93:2469-71.